COMPANIES COVERED
RocheDownload FREE Report Sample
Download Free sampleUrothelial carcinoma or transitional cell carcinoma is a malignant neoplasm occurring from urothelium. The disease is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for approximately 90% of all urinary cancer cases.
Urothelial Cancer Drugs Market contains market size and forecasts of Urothelial Cancer Drugs in Global, including the following market information:
Global Urothelial Cancer Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Urothelial Cancer Drugs market was valued at 1084.2 million in 2021 and is projected to reach US$ 2463.7 million by 2028, at a CAGR of 12.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Urothelial Cancer Drugs include Roche, Merck, Bristol-Myers Squibb, AstraZeneca and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Urothelial Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Urothelial Cancer Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Urothelial Cancer Drugs Market Segment Percentages, by Type, 2021 (%)
Chemotherapy
Immunotherapy
Global Urothelial Cancer Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Urothelial Cancer Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Pharmacy
Global Urothelial Cancer Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Urothelial Cancer Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urothelial Cancer Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Urothelial Cancer Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Pfizer
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
